Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Start-ups

Amphista strikes targeted protein degrader deals with Merck KGaA, BMS

by Michael McCoy
May 6, 2022 | A version of this story appeared in Volume 100, Issue 16

 

Amphista Therapeutics has signed deals with Merck KGaA and Bristol Myers Squibb to discover small-molecule targeted protein degrader therapeutics using its technology. Amphista says the deals are worth a combined $74 million in up-front payments and will focus on oncology, immunology, and other drug targets. Amphista launched in 2020 based on the work of Alessio Ciulli, a chemist at the University of Dundee. The firm says its molecules are more drug-like than traditional targeted protein degraders.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.